Adial Pharmaceuticals, Inc. Stock News

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024.

FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval

New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions

GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024.

Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.